

Supplementary List S1:

List of full text scored papers (n=115; 45 for therapy, 70 for diagnosis including 3 articles for both groups).

[1-112]

- 1 Al-Mayouf, S., Al-Mazyed, A., and Bahabri, S. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate. *Clinical rheumatology*. 2000;**19**:138-141.
- 2 Al-Mayouf, S. M., Laxer, R. M., Schneider, R., Silverman, E. D., and Feldman, B. M. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. *The Journal of rheumatology*. 2000;**27**:2498-2503.
- 3 Bader-Meunier, B., Decaluwe, H., Barnerias, C. et al. Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry. *JRheumatol*. 2011;**38**:1436-1440.
- 4 Balin, S. J., Wetter, D. A., Andersen, L. K., and Davis, M. D. P. Calcinosis cutis occurring in association with autoimmune connective tissue disease: the Mayo Clinic experience with 78 patients, 1996-2009. *Archives of dermatology*. 2012;**148**:455-462.
- 5 Banker, B. Q. Dermatomyositis of childhood, ultrastructural alterations of muscle and intramuscular blood vessels. *JNeuropatholExpNeurol*. 1975;**34**:46-75.
- 6 Bhansing, K. J., Hoppenreijns, E. P., Janssen, A. J. W. M. et al. Quantitative muscle ultrasound : a potential tool for assessment of disease activity in juvenile dermatomyositis. *Scandinavian journal of rheumatology*. 2014;339-341.
- 7 Bilgic, H., Ytterberg, S. R., Amin, S. et al. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. *Arthritis Rheum*. 2009;**60**:3436-3446.
- 8 Bloom, B. J., Tucker, L. B., Miller, L. C., and Schaller, J. G. von Willebrand factor in juvenile dermatomyositis. *The Journal of rheumatology*. 1995;**22**:320-325.
- 9 Cappelletti, C., Baggi, F., Zolezzi, F. et al. Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies. *Neurology*. 2011;**76**:2079-2088.
- 10 Cooper, M. A., Willingham, D. L., Brown, D. E., French, A. R., Shih, F. F., and White, A. J. Rituximab for the treatment of juvenile dermatomyositis: A report of four pediatric patients. *Arthritis and Rheumatism*. 2007;**56**:3107-3111.
- 11 Crowe, W. E., Bove, K. E., Levinson, J. E., and Hilton, P. K. Clinical and pathogenetic implications of histopathology in childhood polydermatomyositis. *Arthritis and rheumatism*. 1982;**25**:126-139.
- 12 Dagher, R., Desjonqueres, M., Duquesne, A. et al. Mycophenolate mofetil in juvenile dermatomyositis: A case series. *Rheumatology International*. 2012;**32**:711-716.
- 13 Dau, P. C. Plasmapheresis in idiopathic inflammatory myopathy. Experience with 35 patients. *Archives of neurology*. 1981;**38**:544-552.
- 14 Davis, W. R., Halls, J. E., Offiah, A. C., Pilkington, C., Owens, C. M., and Rosendahl, K. Assessment of active inflammation in juvenile dermatomyositis: A novel magnetic resonance imaging-based scoring system. *Rheumatology*.

- 2011;**50**:2237-2244.
- 15 Dawkins, M. A., Jorizzo, J. L., Walker, F. O., Albertson, D., Sinal, S. H., and Hinds, A. Dermatomyositis: A dermatology-based case series. *Journal of the American Academy of Dermatology*. 1998;**38**:397-404.
 - 16 De, B. F., De, A. M., Aramini, L. et al. Correlation of serum neopterin concentrations with disease activity in juvenile dermatomyositis. *Arch Dis Child*. 1993;**69**:232-235.
 - 17 Dinh, H. V., McCormack, C., Hall, S., and Prince, H. M. Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. *Journal of the American Academy of Dermatology*. 2007;**56**:148-153.
 - 18 Dolezalova, P., Young, S. P., Bacon, P. A., and Southwood, T. R. Nailfold capillary microscopy in healthy children and in childhood rheumatic diseases: a prospective single blind observational study. *AnnRheumDis*. 2003;**62**:444-449.
 - 19 Dressler, F., Frosch, M., Monkemoller, K., Thon, A., Weissbarth-Riedel, E., and Horneff, G. Results of the German ESPED-recording of new patients with juvenile dermatomyositis (JDM). *KlinPadiatr*. 2011;**223**:280-282.
 - 20 Dubowitz, V. Treatment of dermatomyositis in childhood. *Archives of disease in childhood*. 1976;**51**:494-500.
 - 21 Espada, G., Maldonado Cocco, J. A., Fertig, N., and Oddis, C. V. Clinical and serologic characterization of an Argentine pediatric myositis cohort: Identification of a novel autoantibody (anti-mj) to a 142-kda protein. *JRheumatol*. 2009;**36**:2547-2551.
 - 22 Fischer, T. J., Rachelefsky, G. S., Klein, R. B., Paulus, H. E., and Stiehm, E. R. Childhood dermatomyositis and polymyositis. Treatment with methotrexate and prednisone. *American journal of diseases of children (1960)*. 1979;**133**:386-389.
 - 23 Ghosh, P. S. and Sorenson, E. J. Diagnostic yield of electromyography in children with myopathic disorders. *Pediatric neurology*. 2014;**51**:215-219.
 - 24 Goel, K. M. and King, M. Dermatomyositis-polymyositis in children. *Scottish medical journal*. 1986;**31**:15-19.
 - 25 Gonçalves, F. G. P., Chimelli, L., Sallum, A. M. E., Marie, S. K. N., Kiss, M. H. B., and Ferriani, V. P. L. Immunohistological analysis of CD59 and membrane attack complex of complement in muscle in juvenile dermatomyositis. *The Journal of rheumatology*. 2002;**29**:1301-1307.
 - 26 Gunawardena, H., Wedderburn, L. R., North, J. et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. *Rheumatology(Oxford)*. 2008;**47**:324-328.
 - 27 Gunawardena, H., Wedderburn, L. R., Chinoy, H. et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. *Arthritis and Rheumatism*. 2009;**60**:1807-1814.
 - 28 Guzmán, J., Petty, R. E., and Malleson, P. N. Monitoring disease activity in juvenile dermatomyositis: the role of von Willebrand factor and muscle enzymes. *The Journal of rheumatology*. 1994;**21**:739-743.
 - 29 Harris-Love, M. O., Shrader, J. A., Koziol, D. et al. Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis. *Rheumatology*. 2009;**48**:134-139.
 - 30 Hasija, R., Pistorio, A., Ravelli, A. et al. Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: an international multicenter PRINTO study. *Arthritis and Rheumatism*. 2011;**63**:3142-3152.
 - 31 Hassan, J., van der Net, J. J., and van Royen-Kerkhof, A. Treatment of

- refractory juvenile dermatomyositis with tacrolimus. *Clinical Rheumatology*. 2008;**27**:1469-1471.
- 32 Heckmatt, J., Hasson, N., Saunders, C. et al. Cyclosporin in juvenile dermatomyositis. *Lancet*. 1989;**1**:1063-1066.
- 33 Hernandez, R. J., Sullivan, D. B., Chenevert, T. L., and Keim, D. R. MR imaging in children with dermatomyositis: musculoskeletal findings and correlation with clinical and laboratory findings. *AJR AmJRoentgenol*. 1993;**161**:359-366.
- 34 Huang, J. L. Long-term prognosis of patients with juvenile dermatomyositis initially treated with intravenous methylprednisolone pulse therapy. *Clinical and experimental rheumatology*. 1999;**17**:621-624.
- 35 Huber, A. M., Feldman, B. M., Rennebohm, R. M. et al. Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. *Arthritis and Rheumatism*. 2004;**50**:1595-1603.
- 36 Huber, A. M., Dugan, E. M., Lachenbruch, P. A. et al. The cutaneous assessment tool: Development and reliability in juvenile idiopathic inflammatory myopathy. *Rheumatology*. 2007;**46**:1606-1611.
- 37 Huber, A. M., Lachenbruch, P. A., Dugan, E. M., Miller, F. W., and Rider, L. G. Alternative scoring of the Cutaneous Assessment Tool in juvenile dermatomyositis: results using abbreviated formats. *Arthritis Rheum*. 2008;**59**:352-356.
- 38 Huber, A. M., Dugan, E. M., Lachenbruch, P. A. et al. Preliminary validation and clinical meaning of the Cutaneous Assessment Tool in juvenile dermatomyositis. *Arthritis Rheum*. 2008;**59**:214-221.
- 39 Huber, A. M., Giannini, E. H., Bowyer, S. L. et al. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference. *Arthritis care & research*. 2010;**62**:219-225.
- 40 Huber, A. M., Robinson, A. B., Reed, A. M. et al. Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference. *Arthritis care & research*. 2012;**64**:546-553.
- 41 Ingegnoli, F., Zeni, S., Gerloni, V., and Fantini, F. Capillaroscopic observations in childhood rheumatic diseases and healthy controls. *ClinExpRheumatol*. 2005;**23**:905-911.
- 42 Ishikawa, A., Muro, Y., Sugiura, K., and Akiyama, M. Development of an ELISA for detection of autoantibodies to nuclear matrix protein 2. *Rheumatology (United Kingdom)*. 2012;**51**:1181-1187.
- 43 Jacobs, J. C. Methotrexate and azathioprine treatment of childhood dermatomyositis. *Pediatrics*. 1977;**59**:212-218.
- 44 Jain, M., Smith, M., Cintas, H. et al. Intra-rater and inter-rater reliability of the 10-point Manual Muscle Test (MMT) of strength in children with juvenile idiopathic inflammatory myopathies (JIIM). *Physical and Occupational Therapy in Pediatrics*. 2006;**26**:5-17.
- 45 Kim, S., El-Hallak, M., Dedeoglu, F., Zurakowski, D., Fuhlbrigge, R. C., and Sundel, R. P. Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment. *Arthritis and Rheumatism*. 2009;**60**:1825-1830.
- 46 Kobayashi, I., Okura, Y., Yamada, M., Kawamura, N., Kuwana, M., and Ariga,

- T. Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. *The Journal of pediatrics*. 2011;**158**:675-677.
- 47 Ladd, P. E., Emery, K. H., Salisbury, S. R., Laor, T., Lovell, D. J., and Bove, K. E. Juvenile dermatomyositis: Correlation of MRI at presentation with clinical outcome. *American Journal of Roentgenology*. 2011;**197**:W153-W158.
- 48 Lam, C. G., Manlihot, C., Pullenayegum, E. M., and Feldman, B. M. Efficacy of intravenous Ig therapy in juvenile dermatomyositis. *Annals of the Rheumatic Diseases*. 2011;**70**:2089-2094.
- 49 Lang, B. and Dooley, J. Failure of pulse intravenous methylprednisolone treatment in juvenile dermatomyositis. *The Journal of pediatrics*. 1996;**128**:429-432.
- 50 Lang, B. A., Laxer, R. M., Murphy, G., Silverman, E. D., and Roifman, C. M. Treatment of dermatomyositis with intravenous gammaglobulin. *The American journal of medicine*. 1991;**91**:169-172.
- 51 Laxer, R. M., Stein, L. D., and Petty, R. E. Intravenous pulse methylprednisolone treatment of juvenile dermatomyositis. *Arthritis and rheumatism*. 1987;**30**:328-334.
- 52 Li, C. K., Varsani, H., Holton, J. L., Gao, B., Woo, P., and Wedderburn, L. R. MHC Class I overexpression on muscles in early juvenile dermatomyositis. *JRheumatol*. 2004;**31**:605-609.
- 53 Lovell, D. J., Lindsley, C. B., Rennebohm, R. M. et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. *The Juvenile Dermatomyositis D. Arthritis Rheum*. 1999;**42**:2213-2219.
- 54 Maillard, S. M., Jones, R., Owens, C. et al. Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis. *Rheumatology*. 2004;**43**:603-608.
- 55 Malattia, C., Damasio, M. B., Madeo, A. et al. Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis. *Annals of the Rheumatic Diseases*. 2013
- 56 McCann, L. J., Garay, S. M., Ryan, M. M., Harris, R., Riley, P., and Pilkington, C. A. Oropharyngeal dysphagia in juvenile dermatomyositis (JDM): An evaluation of videofluoroscopy swallow study (VFSS) changes in relation to clinical symptoms and objective muscle scores. *Rheumatology*. 2007;**46**:1363-1366.
- 57 Miller, G., Heckmatt, J. Z., and Dubowitz, V. Drug treatment of juvenile dermatomyositis. *Archives of disease in childhood*. 1983;**58**:445-450.
- 58 Miller, L. C., Michael, A. F., and Kim, Y. Childhood dermatomyositis. Clinical course and long-term follow-up. *Clinical pediatrics*. 1987;**26**:561-566.
- 59 Miller, L. C., Michael, A. F., Baxter, T. L., and Kim, Y. Quantitative muscle testing in childhood dermatomyositis. *Archives of physical medicine and rehabilitation*. 1988;**69**:610-613.
- 60 Miller, L. C., Sisson, B. A., Tucker, L. B., DeNardo, B. A., and Schaller, J. G. Methotrexate treatment of recalcitrant childhood dermatomyositis. *Arthritis and rheumatism*. 1992;**35**:1143-1149.
- 61 Montecucco, C., Ravelli, A., Caporali, R. et al. Autoantibodies in juvenile dermatomyositis. *ClinExpRheumatol*. 1990;**8**:193-196.
- 62 Morinishi, Y., Oh-ishi, T., Kabuki, T., and Joh, K. Juvenile dermatomyositis:

- clinical characteristics and the relatively high risk of interstitial lung disease. *ModRheumatol*. 2007;**17**:413-417.
- 63 Nascif, A. K. S., Terreri, M. T. R. A. T., Len, C. A., Andrade, L. E. C., and Hilario, M. O. E. Inflammatory myopathies in childhood: correlation between nailfold capillaroscopy findings and clinical and laboratory data. *Jornal de Pediatria*. 2006;**82**:40-45.
- 64 Newman, E. D. and Garbes, A. D. Needle muscle biopsy: An important clinic-based procedure for the rheumatologist. *Journal of Clinical Rheumatology*. 1997;**3**:69-74.
- 65 Ng, Y. T., Ouvrier, R. A., and Wu, T. Drug therapy in juvenile dermatomyositis: follow-up study. *Journal of child neurology*. 1998;**13**:109-112.
- 66 Niakan, E., Pitner, S. E., Whitaker, J. N., and Bertorini, T. E. Immunosuppressive agents in corticosteroid-refractory childhood dermatomyositis. *Neurology*. 1980;**30**:286-291.
- 67 Nussbaum, A. I., Silver, R. M., and Maricq, H. R. Serial changes in nailfold capillary morphology in childhood dermatomyositis. *Arthritis Rheum*. 1983;**26**:1169-1172.
- 68 Oddis, C. V., Reed, A. M., Aggarwal, R. et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. *Arthritis and rheumatism*. 2013;**65**:314-324.
- 69 Olson, N. Y. and Lindsley, C. B. Adjunctive use of hydroxychloroquine in childhood dermatomyositis. *The Journal of rheumatology*. 1989;**16**:1545-1547.
- 70 Owlia, M. B. and Forghanizadeh, J. Needle muscle biopsy using pleural biopsy needle for diagnosis of inflammatory muscle diseases. *Journal, Indian Academy of Clinical Medicine*. 2005;**6**:281-284.
- 71 Pachman, L. M., Friedman, J. M., Maryjowski-Sweeney, M. L. et al. Immunogenetic studies of juvenile dermatomyositis. III. Study of antibody to organ-specific and nuclear antigens. *Arthritis Rheum*. 1985;**28**:151-157.
- 72 Pachman, L. M., Liotta-Davis, M. R., Hong, D. K. et al. TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. *Arthritis Rheum*. 2000;**43**:2368-2377.
- 73 Pachman, L. M., Fedczyna, T. O., Lechman, T. S., and Lutz, J. Juvenile dermatomyositis: the association of the TNF alpha-308A allele and disease chronicity. *CurrRheumatolRep*. 2001;**3**:379-386.
- 74 Park, J. H., Vital, T. L., Ryder, N. M. et al. Magnetic resonance imaging and P-31 magnetic resonance spectroscopy provide unique quantitative data useful in the longitudinal management of patients with dermatomyositis. *Arthritis Rheum*. 1994;**37**:736-746.
- 75 Piotto, D. G., Len, C. A., Hilario, M. O., and Terreri, M. T. Nailfold capillaroscopy in children and adolescents with rheumatic diseases. *RevBrasReumatol*. 2012;**52**:722-732.
- 76 Pistoia, V., Buoncompagni, A., Scribanis, R. et al. Cyclosporin A in the treatment of juvenile chronic arthritis and childhood polymyositis-dermatomyositis. Results of a preliminary study. *Clinical and experimental rheumatology*. 1993;**11**:203-208.
- 77 Ponyi, A., Constantin, T., Balogh, Z. et al. Disease course, frequency of relapses and survival of 73 patients with juvenile or adult dermatomyositis. *Clinical and Experimental Rheumatology*. 2005;**23**:50-56.
- 78 Pouessel, G., Deschildre, A., Le Bourgeois, M. et al. The lung is involved in

- juvenile dermatomyositis. *Pediatric Pulmonology*. 2012
- 79 Prestridge, A., Morgan, G., Ferguson, L., Huang, C.-C., and Pachman, L. M. Pulmonary function tests in idiopathic inflammatory myopathy: Association with clinical parameters in children. *Arthritis care & research*. 2013
- 80 Quiñones, R., Morgan, G. A., Amoruso, M., Field, R., Huang, C.-C., and Pachman, L. M. Four-year-olds, healthy or recovering from Juvenile Dermatomyositis, do not achieve a full score on the Childhood Myositis Assessment Scale (CMAS). *Arthritis care & research*. 2013NA.
- 81 Ramanan, A. V., Campbell-Webster, N., Ota, S. et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. *Arthritis and Rheumatism*. 2005;**52**:3570-3578.
- 82 Reed, A. M., Peterson, E., Bilgic, H. et al. Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course. *Arthritis and Rheumatism*. 2012;**64**:4078-4086.
- 83 Reiff, A., Rawlings, D. J., Shaham, B. et al. Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. *The Journal of rheumatology*. 1997;**24**:2436-2443.
- 84 Rennebohm, R. M., Jones, K., Huber, A. M. et al. Normal scores for nine maneuvers of the Childhood Myositis Assessment Scale. *Arthritis Care and Research*. 2004;**51**:365-370.
- 85 Rider, L. G., Schiffenbauer, A. S., Zito, M. et al. Neopterin and quinolinic acid are surrogate measures of disease activity in the juvenile idiopathic inflammatory myopathies. *ClinChem*. 2002;**48**:1681-1688.
- 86 Rider, L. G., Koziol, D., Giannini, E. H. et al. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. *Arthritis Care and Research*. 2010;**62**:465-472.
- 87 Riisager, M., Mathiesen, P. R., Vissing, J., Preisler, N., and Ørngreen, M. C. Aerobic training in persons who have recovered from juvenile dermatomyositis. *Neuromuscular disorders : NMD*. 2013;**23**:962-968.
- 88 Riley, P., Maillard, S. M., Wedderburn, L. R., Woo, P., Murray, K. J., and Pilkington, C. A. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. *Rheumatology*. 2004;**43**:491-496.
- 89 Riley, P., McCann, L. J., Maillard, S. M., Woo, P., Murray, K. J., and Pilkington, C. A. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. *Rheumatology*. 2008;**47**:877-880.
- 90 Rouster-Stevens, K. A., Morgan, G. A., Wang, D., and Pachman, L. M. Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis. *Arthritis Care Res(Hoboken)*. 2010;**62**:1446-1451.
- 91 Rouster-Stevens, K. A., Ferguson, L., Morgan, G., Huang, C.-C., and Pachman, L. M. Pilot study of etanercept in patients with refractory juvenile dermatomyositis. *Arthritis care & research*. 2014;**66**:783-787.
- 92 Sakuta, R., Murakami, N., Jin, Y., Nagai, T., Nonaka, I., and Nishino, I. Diagnostic significance of membrane attack complex and vitronectin in childhood dermatomyositis. *JChild Neurol*. 2005;**20**:597-602.
- 93 Sallum, A. M. E., Marie, S. K. N., Wakamatsu, A. et al. Immunohistochemical analysis of adhesion molecule expression on muscle biopsy specimens from patients with juvenile dermatomyositis. *JRheumatol*. 2004;**31**:801-807.
- 94 Sallum, A. M. E., Kiss, M. H. B., Silva, C. A. A. et al. MHC class I and II

- expression in juvenile dermatomyositis skeletal muscle. *Clinical and Experimental Rheumatology*. 2009;**27**:519-526.
- 95 Sansome, A. and Dubowitz, V. Intravenous immunoglobulin in juvenile dermatomyositis--four year review of nine cases. *Archives of disease in childhood*. 1995;**72**:25-28.
- 96 Savioli, C., Silva, C. A. A., Fabri, G. M. C. et al. Gingival capillary changes and oral motor weakness in juvenile dermatomyositis. *Rheumatology*. 2010;**49**:1962-1970.
- 97 Scheja, A., Elborgh, R., and Wildt, M. Decreased capillary density in juvenile dermatomyositis and in mixed connective tissue disease. *The Journal of rheumatology*. 1999;**26**:1377-1381.
- 98 Schmeling, H., Stephens, S., Goia, C. et al. Nailfold capillary density is importantly associated over time with muscle and skin disease activity in juvenile dermatomyositis. *Rheumatology*. 2011;**50**:885-893.
- 99 Schwartz, T., Sanner, H., Gjesdal, O., Flatø, B., and Sjaastad, I. In juvenile dermatomyositis, cardiac systolic dysfunction is present after long-term follow-up and is predicted by sustained early skin activity. *Annals of the rheumatic diseases*. 2014;**73**:1805-1810.
- 100 Seshadri, R., Feldman, B. M., Ilowite, N., Cawkwell, G., and Pachman, L. M. The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis. *Arthritis and rheumatism*. 2008;**59**:989-995.
- 101 Shah, M., Mamyrova, G., Targoff, I. N. et al. The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. *Medicine (Baltimore)*. 2013;**92**:25-41.
- 102 Shahi, V., Wetter, D. A., Howe, B. M., Ringler, M. D., and Davis, M. D. P. Plain radiography is effective for the detection of calcinosis cutis occurring in association with autoimmune connective tissue disease. *The British journal of dermatology*. 2014;**170**:1073-1079.
- 103 Shinjo, S. K., Sallum, A. M. E., Silva, C. A., and Marie, S. K. N. Skeletal muscle major histocompatibility complex class I and II expression differences in adult and juvenile dermatomyositis. *Clinics (São Paulo, Brazil)*. 2012;**67**:885-890.
- 104 Silver, R. M. and Maricq, H. R. Childhood dermatomyositis: serial microvascular studies. *Pediatrics*. 1989;**83**:278-283.
- 105 Smith, R. L., Sundberg, J., Shamiyah, E., Dyer, A., and Pachman, L. M. Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops. *JRheumatol*. 2004;**31**:1644-1649.
- 106 Spencer-Green, G., Schlesinger, M., Bove, K. E. et al. Nailfold capillary abnormalities in childhood rheumatic diseases. *JPediatr*. 1983;**102**:341-346.
- 107 Tabarki, B., Ponsot, G., Prieur, A. M., and Tardieu, M. Childhood dermatomyositis: clinical course of 36 patients treated with low doses of corticosteroids. *European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society*. 1998;**2**:205-211.
- 108 Tansley, S. L., Betteridge, Z. E., Gunawardena, H. et al. Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. *Arthritis research & therapy*. 2014;**16**:R138.
- 109 Tansley, S. L., Betteridge, Z. E., Shaddick, G. et al. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at

- disease onset. *Rheumatology (Oxford, England)*. 2014;**53**:2204-2208.
- 110 Targoff, I. N., Mamyrova, G., Trieu, E. P. et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. *Arthritis and Rheumatism*. 2006;**54**:3682-3689.
 - 111 Wedderburn, L. R., Varsani, H., Li, C. K. C. et al. International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials. *Arthritis Care and Research*. 2007;**57**:1192-1201.
 - 112 Zeller, V., Cohen, P., Prieur, A. M., and Guillevin, L. Cyclosporin a therapy in refractory juvenile dermatomyositis. Experience and longterm followup of 6 cases. *The Journal of rheumatology*. 1996;**23**:1424-1427.